ASCO 2025: The leaders of Daiichi-Sankyo discuss new data for the ADC ENHERTU in 1L HER2+ breast cancer and 2L HER2+ gastric cancer, plus new targets that are emerging

Jun 2, 2025
1 min read

Global Head of Oncology Ken Keller walks us through the company's ASCO data and highlights other future catalysts to watch, which new Global CEO Hiroyuki Okuzawa discusses the company's long-term plans to be a top 10 oncology company.

https://vimeo.com/1089784377

Recent Posts

See All

Oxford based Infinitopes raised an additional $15.4M in a second closing of its seed round to bring the total raised to $35.1M. It will have clinical data on its cancer vaccine by the end of the year

Upstream Bio's CEO Rand Sutherland discusses today's severe asthma data for verekitug, a TSLP receptor antagonist

SLAS 2026: Atinary showed BiotechTV the "Self Driving Lab" it has created in the Seaport that integrates machine learning into the experiment design and optimization process to accelerate science

ASCO 2025: The leaders of Daiichi-Sankyo discuss new data for the ADC ENHERTU in 1L HER2+ breast cancer and 2L HER2+ gastric cancer, plus new targets that are emerging

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight